Actively Recruiting
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Led by National Taiwan University Hospital · Updated on 2024-12-18
20
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody
CONDITIONS
Official Title
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with amyotrophic lateral sclerosis (ALS) aged over 20 years with plasma anti-NRIP autoantibody
- Agree to receive plasmapheresis intervention
- Agree to participate in the trial and receive serial examinations and follow up
You will not qualify if you...
- Patients without plasma anti-NRIP autoantibody
- Patients requiring permanent ventilator support for ALS progression
- Unable to receive plasmapheresis or trial-related examinations
- Pregnancy
- Blood fibrinogen level less than 50 mg/dl
- Specific ALS subtypes including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, 100
Actively Recruiting
Research Team
L
Li-Kai Tsai, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here